

# Emire Seyahi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9558296/publications.pdf>

Version: 2024-02-01

90  
papers

3,205  
citations

201674

27  
h-index

161849

54  
g-index

93  
all docs

93  
docs citations

93  
times ranked

3786  
citing authors

#	ARTICLE	IF	CITATIONS
1	Orbital Mass as the Only Presenting Sign with Overlapping Features of Lupus Erythematosus Panniculitis and Subcutaneous Panniculitis-Like T-Cell Lymphoma. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 717-720.	1.8	1
2	Patients with rheumatic diseases are ready to use social media in clinical practice; what about rheumatologists? A cross-sectional survey. <i>Rheumatology International</i> , 2022, 42, 717-723.	3.0	3
3	Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine. <i>Journal of Medical Virology</i> , 2022, 94, 3431-3437.	5.0	4
4	Safety of SARS-CoV-2 vaccination in patients with Behçet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine. <i>Rheumatology International</i> , 2022, 42, 973-987.	3.0	16
5	Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review. <i>Rheumatology</i> , 2022, 62, 9-18.	1.9	2
6	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	6.2	26
7	Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. <i>Rheumatology International</i> , 2021, 41, 1105-1114.	3.0	96
8	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 651715.	4.8	15
9	Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. <i>Rheumatology International</i> , 2021, 41, 1429-1440.	3.0	71
10	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. <i>Rheumatology International</i> , 2021, , 1.	3.0	3
11	The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. <i>Rheumatology International</i> , 2021, , 1.	3.0	8
12	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 3-13.	0.8	1
13	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-13.	0.8	17
14	Peripheral blood mononuclear cell proteome profile in Behçet's syndrome. <i>Rheumatology International</i> , 2020, 40, 65-74.	3.0	6
15	Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome. <i>Rheumatology</i> , 2020, 59, 799-806.	1.9	27
16	Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. <i>Rheumatology</i> , 2020, 59, 2264-2271.	1.9	21
17	Venous involvement in inflammatory disorders. <i>Current Opinion in Rheumatology</i> , 2020, 32, 29-34.	4.3	4
18	Characteristics and outcomes of Behçet's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients. <i>Internal and Emergency Medicine</i> , 2020, 15, 1567-1571.	2.0	22

#	ARTICLE	IF	CITATIONS
19	The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. <i>Rheumatology International</i> , 2020, 40, 1229-1238.	3.0	68
20	Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: reply. <i>Rheumatology</i> , 2020, 59, 914-915.	1.9	0
21	Vascular and Cardiac Involvement. , 2020, , 83-103.		2
22	The Prognosis of Behçet Syndrome. , 2020, , 243-260.		0
23	Investigation of clinical profile of Behçet's syndrome-related versus idiopathic branch retinal vein occlusion. <i>Indian Journal of Ophthalmology</i> , 2020, 68, 1876.	1.1	1
24	Current surgical approaches in Takayasu's arteritis: a single-centre experience. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 31-41.	0.8	0
25	Takayasu's arteritis: associated inflammatory diseases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 61-68.	0.8	2
26	One year in review 2020: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 3-10.	0.8	6
27	SP065 DISEASE CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RENAL ARTERY STENOSIS FOLLOWED BY A SINGLE NEPHROLOGY CENTER. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
28	FP095 ETIOLOGICAL EVALUATION AND MORTALITY OF PATIENTS WITH RENAL ARTERY STENOSIS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
29	240.â€fFACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
30	Assessment of deep venous thrombosis in the lower extremity in Behçet's syndrome: MR venography versus Doppler ultrasonography. <i>Internal and Emergency Medicine</i> , 2019, 14, 705-711.	2.0	13
31	Secukinumab induced Behçet's syndrome: a report of two cases. <i>Oxford Medical Case Reports</i> , 2019, omz041.	0.4	26
32	Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. <i>Rheumatology International</i> , 2019, 39, 911-919.	3.0	37
33	Increased vein wall thickness in Behçet disease. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2019, 7, 677-684.e2.	1.6	30
34	Phenotypes in Behçet's syndrome. <i>Internal and Emergency Medicine</i> , 2019, 14, 677-689.	2.0	80
35	THU0298â€...INITIAL MANIFESTATIONS AND OUTCOME OF PATIENTS WITH INCOMPLETE BEHÇET'S SYNDROME. , 2019, , .		0
36	FRI0279â€...MYCOPHENOLATE MOFETIL IN THE TREATMENT OF MAJOR ORGAN INVOLVEMENT OF PATIENTS WITH BEHÇET'S SYNDROME. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	SAT0223â€¦FACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS. , 2019, , .		1
38	Is sirolimus a treatment option for patients with systemic lupus erythematosus?. Clinical and Experimental Rheumatology, 2019, 37 Suppl 122, 13.	0.8	0
39	Familial Mediterranean fever: misdiagnosis and diagnostic delay in Turkey. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 119-124.	0.8	2
40	Biosimilar infliximab for Behçet's syndrome: a case series. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 111-115.	0.8	3
41	Outcome of invasive procedures for venous thrombosis in Behçet's syndrome: case series and systematic literature review. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 125-131.	0.8	2
42	One year in review 2019: Behçet's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 3-17.	0.8	12
43	Increased frequency of obstructive sleep apnea syndrome in Behçet's syndrome patients with superior vena cava syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 132-136.	0.8	0
44	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatology International, 2018, 38, 607-622.	3.0	12
45	Behçet syndrome: a contemporary view. Nature Reviews Rheumatology, 2018, 14, 107-119.	8.0	281
46	Surgical Treatment of Pulmonary Complications in Behçet's Syndrome. Seminars in Thoracic and Cardiovascular Surgery, 2018, 30, 369-378.	0.6	16
47	One year in review 2018: Behçet's syndrome. Clinical and Experimental Rheumatology, 2018, 36, 13-27.	0.8	9
48	Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. Nature Genetics, 2017, 49, 438-443.	21.4	129
49	Takayasu arteritis: an update. Current Opinion in Rheumatology, 2017, 29, 51-56.	4.3	128
50	Missing Information About Disease Controls: Comment on the Article by Mangnus et al. Arthritis and Rheumatology, 2017, 69, 678-678.	5.6	0
51	Myelopathy in Behçet's disease: The Bagel Sign. Annals of Neurology, 2017, 82, 288-298.	5.3	46
52	Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals. European Journal of Internal Medicine, 2017, 37, e34-e36.	2.2	0
53	About the AIRTRIP randomised clinical trial: comments on the article by Brucato et al. Clinical and Experimental Rheumatology, 2017, 35 Suppl 104, 17.	0.8	0
54	One year in review 2017: Behçet's syndrome. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 3-15.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 95-99.	0.8	6
56	Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 86-89.	0.8	9
57	Behçet syndrome: the vascular cluster. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 1277-1280.	0.9	14
58	A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2208-2211.	0.9	59
59	Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. <i>Rheumatology International</i> , 2016, 36, 1719-1725.	3.0	20
60	Behçet's disease: How to diagnose and treat vascular involvement. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 279-295.	3.3	102
61	Infliximab is a plausible alternative for neurologic complications of Behçet disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e258.	6.0	55
62	Effect of colchicine on serum lipid levels. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S136.	0.8	1
63	To anticoagulate or not to anticoagulate vascular thrombosis in Behçet's syndrome: an enduring question. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S3-4.	0.8	8
64	Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 92-96.	0.8	13
65	One year in review 2016: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 10-22.	0.8	16
66	Clinical and Ultrasonographic Evaluation of Lower-extremity Vein Thrombosis in Behcet Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1899.	1.0	53
67	Venous claudication in Behçet's disease. <i>Journal of Vascular Surgery</i> , 2015, 62, 698-703.e1.	1.1	7
68	Pulmonary artery involvement in Behçet's syndrome: Effects of anti-Tnf treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 369-373.	3.4	64
69	Response to the letter by Andrea Mancuso. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, e2.	3.4	0
70	Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , 2015, 27, 18-23.	4.3	40
71	An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 602-609.	3.4	59
72	Behçet's syndrome: a critical digest of the 2014-2015 literature. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S3-14.	0.8	63

#	ARTICLE	IF	CITATIONS
73	Vein wall imaging in Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S7-8.	0.8	9
74	Right ventricular thrombus and tricuspid valve dysfunction in a patient with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S109-11.	0.8	10
75	Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. <i>Nature Genetics</i> , 2013, 45, 202-207.	21.4	483
76	Aortic and coronary calcifications in Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 96-104.	3.4	33
77	Fever in Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 64-7.	0.8	21
78	Pulmonary Artery Involvement and Associated Lung Disease in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 35-48.	1.0	151
79	Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease. <i>Journal of Vascular Surgery</i> , 2012, 55, 157-163.	1.1	78
80	Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever. <i>Rheumatology International</i> , 2012, 32, 1955-1962.	3.0	15
81	Major vessel thrombosis in Behçet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 735-40.	0.8	33
82	The estimated pulmonary artery pressure can be elevated in Behçet's syndrome. <i>Respiratory Medicine</i> , 2011, 105, 1739-1747.	2.9	16
83	BEHÇET'S SYNDROME AND THROMBOSIS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011026.	1.3	92
84	A twin study in Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S62-6.	0.8	20
85	The prevalence of Behçet's syndrome, familial Mediterranean fever, HLA-B51 and MEFV gene mutations among ethnic Armenians living in Istanbul, Turkey. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S67-75.	0.8	11
86	Atherosclerosis in Behçet's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 1-12.	3.4	76
87	The management of Behçet's syndrome. <i>Acta Reumatologica Portuguesa</i> , 2006, 31, 125-31.	0.2	5
88	Pulmonary artery aneurysms in Behçet syndrome. <i>American Journal of Medicine</i> , 2004, 117, 867-870.	1.5	224
89	Subclinical Atherosclerosis and Oxidized LDL Levels in Familial Mediterranean Fever. <i>Cumhuriyet Medical Journal</i> , 0, , .	0.1	0
90	Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behçet's syndrome. <i>Rheumatology International</i> , 0, , .	3.0	2